glp-1 and fatty liver disease Receptor Agonists in Non-Alcoholic Disease: Current Evidence Future Perspectives GLP-1 and fatty liver disease.

Why Eating Enough Still Matters Even when appetite is low, nutrition continues to play an important role

J Cardiovasc Dev Dis

The FDA has explicitly stated that there are no FDA-approved GLP-1 patches or drug products containing common patch ingredients like berberine

For example, in the EMPA-REG OUTCOME trial, patients randomized to receive empagliflozin experienced a significant reduction in cardiovascular death, all-cause mortality, and hospitalization for heart failure compared to placebo despite only modest differences in HbA1c between groups [22]

Modified from Lim et al

This is why we emphasize the importance of monitoring